Gilead Sciences stock returns 11.61% annually over 20 years

scanx
Reviewed by
Radhika SScanX News Team
Key Highlights

Gilead Sciences has delivered an average annual return of 11.61% over the last 20 years, outpacing the market by 2.3% annually. With a current market cap of $155.75 billion, a $100 investment made two decades ago would now be worth $903.01.

powered bylight_fuzz_icon
43279566

*this image is generated using AI for illustrative purposes only.

Gilead Sciences has generated an average annual return of 11.61% over the past 20 years, outperforming the market by 2.3% on an annualized basis. The biopharmaceutical company currently holds a market capitalization of $155.75 billion. This long-term performance highlights the impact of compounded returns on investor wealth over extended periods.

Investment Growth Analysis

If an investor had purchased $100 worth of Gilead Sciences stock 20 years ago, that investment would be valued at $903.01 today. This calculation is based on the company's current share price of $125.45. The substantial growth underscores the potential benefits of long-term equity investments in established healthcare entities.

Key Performance Metrics

Metric Value
Average Annual Return 11.61%
Market Outperformance vs Market 2.3%
Current Market Capitalization $155.75 billion
Current Share Price $125.45
20-Year Growth on $100 Investment $903.01

The data illustrates how consistent returns can significantly multiply initial capital over a 20-year horizon. Gilead Sciences' ability to deliver market-beating returns has resulted in nearly a nine-fold increase on a hypothetical investment made two decades ago.

Disclaimer: This article is AI-generated using data from ViewTrade. ScanX is not liable for any inaccuracies.

Can Gilead Sciences sustain its historical 11.61% annual return given current patent cliffs and pipeline developments?

How will the company's $155.75 billion market cap limit its future growth potential compared to the last two decades?

What impact will recent shifts in healthcare policy and pricing regulations have on Gilead's future profitability?

like15
dislike

Cantor Fitzgerald reiterates Overweight on Gilead Sciences

scanx
Reviewed by
Radhika SScanX News Team
Key Highlights

Cantor Fitzgerald analyst Carter Gould has reiterated an Overweight rating on Gilead Sciences, maintaining a price target of $155.

powered bylight_fuzz_icon
43167186

*this image is generated using AI for illustrative purposes only.

Cantor Fitzgerald analyst Carter Gould has reaffirmed an Overweight rating for Gilead Sciences, maintaining a price target of $155. The reiteration signals continued confidence in the pharmaceutical company's stock performance.

The rating and price target were issued by Cantor Fitzgerald, covering Gilead Sciences (NASDAQ: GILD). The $155 target provides a reference point for investors regarding the stock's potential valuation.

Firm Analyst Rating Price Target
Cantor Fitzgerald Carter Gould Overweight $155
Disclaimer: This article is AI-generated using data from ViewTrade. ScanX is not liable for any inaccuracies.

What upcoming clinical trial results could significantly influence Gilead's stock performance?

How might recent regulatory changes impact Gilead's revenue projections?

What are the potential risks to achieving the $155 price target?

like19
dislike

More News on Gilead Sciences